RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia (RELIEF)
2026年6月4日 更新者:Kriya Therapeutics, Inc.
A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, and PRELIminary EFficacy of Percutaneous Injection of RP-008 Followed by Daily Oral Varenicline in Patients With Trigeminal Neuralgia (The RELIEF Study)
The goal of this study is to evaluate if KRIYA-748 (RP-008) is safe, tolerable, and preliminary effective in treating trigeminal neuralgia (TN) when used in combination with varenicline tartrate.
The study will also assess what doses of RP-008 are safe and tolerable for participants and how the severity of participants' TN pain and frequency of facial pain attacks are affected.
研究概览
研究类型
介入性
注册 (估计的)
24
阶段
- 阶段2
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:VP Medical Affairs
- 电话号码:984-884-5058
- 邮箱:clinicaltrials@kriyatx.com
学习地点
-
-
-
Sherbrooke、加拿大
- 招聘中
- Kriya Clinical Study Site
-
接触:
- Clinical Projects Coordinator
- 电话号码:+1 819-346-1110
- 邮箱:chus@ssss.gouv.qc.ca
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Participant is capable of providing signed informed consent.
- Participant must be between 18 to 80 years of age (inclusive), at the time of signing the informed consent.
- Confirmed diagnosis of classical or idiopathic TN according to the criteria of the International Classification of Headache Disorders-3rd edition (ICHD-3, 2018).
- The diagnosis of TN established at least 6 months prior to Screening.
- Participant has purely unilateral pain attacks limited primarily to the maxillary (V2) and/or mandibular (V3) division of the trigeminal nerve.
- Participant has failed at least 1 standard of care anti-epileptic agent (e.g., carbamazepine, oxcarbazepine, pregabalin, gabapentin, phenytoin, lamotrigine). Failure to a prior anti-epileptic medication is defined as insufficient pain relief despite use of a therapeutic dose for an adequate duration of time or being unsuitable due to contraindications or intolerance to side effects.
- Participant is on stable dosage of any TN anti-epileptic agent(s) for a minimum of 6 weeks prior to Screening.
Exclusion Criteria:
- Participant has bilateral TN pain attacks.
- Participants with secondary TN, defined by ICHD-3 as TN caused by an underlying disease (e.g., tumor in the cerebellopontine angle, arteriovenous malformation, or multiple sclerosis).
- Participants with facial pain not meeting the ICHD-3 diagnostic criteria for either classical or idiopathic TN, including: trigeminal autonomic cephalalgias, cluster headache, hemicrania continua, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA).
- Participants who had no change in pain after taking sodium channel blockers despite the use of a therapeutic dose for an adequate duration of time.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Participants receiving RP-008
Participants will receive a single dose of RP-008 on Day 1 at varying dose levels according to the dose escalation study design.
In addition, varenicline tartrate and oral corticosteroid (equivalent to prednisone or prednisolone) will be administered during the pre- and post-treatment follow-up periods.
|
RP-008 will be administered as a single percutaneous injection to the trigeminal ganglion.
其他名称:
Varenicline tartrate will be administered as a daily oral tablet.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence and severity of adverse events, abnormal clinical laboratory values, abnormal physical examinations, abnormal vital signs, abnormal electrocardiograms (ECGs), and suicidal ideation
大体时间:12 months
|
Safety of RP-008 with varenicline
|
12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of responders, defined as participants with reduced TN pain score, attacks, and severity, to RP-008 with varenicline treatment
大体时间:3 and 12 months
|
Efficacy of RP-008 with varenicline
|
3 and 12 months
|
|
Change in pain as assessed by the 11-point Numerical Pain Rating Scale (NRS), where 0 corresponds to "no pain" and 10 corresponds to "pain as bad as you can imagine"
大体时间:3 and 12 months
|
Efficacy of RP-008 with varenicline
|
3 and 12 months
|
|
Change in pain as assessed by the Brief Pain Inventory (BPI) Pain Interference (PI) sub-scale, where 0 corresponds to pain having no interference with daily activities and 10 corresponds to pain interfering completely with daily activities
大体时间:3 and 12 months
|
Efficacy of RP-008 with varenicline
|
3 and 12 months
|
|
Change from baseline in Pittsburgh Sleep Quality Index (PSQI), where scores range from 0-21 and higher score indicates worse sleep quality
大体时间:3 and 12 months
|
Efficacy of RP-008 with varenicline
|
3 and 12 months
|
|
Change from baseline in Hospital Anxiety and Depression Scale (HADS), where sub-scale scores range from 0-21 and higher score indicates greater symptom severity
大体时间:3 and 12 months
|
Efficacy of RP-008 with varenicline
|
3 and 12 months
|
|
Change from baseline in Work Productivity and Activity Impairment (WPAI): Neuropathic Pain v2.0, where scores are expressed as 0-100% and higher percentage indicates greater impairment
大体时间:3 and 12 months
|
Efficacy of RP-008 with varenicline
|
3 and 12 months
|
|
Change from baseline in Penn Facial Pain Scale Revised (Penn-FPS-R), where scores range from 0-120 and higher score indicates greater pain-related disability
大体时间:3 and 12 months
|
Efficacy of RP-008 with varenicline
|
3 and 12 months
|
|
Change from baseline in 5-level EuroQual-5D (EQ-5D-5L), where scores range from 0-100 and higher scores indicate better health status
大体时间:3 and 12 months
|
Efficacy of RP-008 with varenicline
|
3 and 12 months
|
|
Change from baseline in Patient Global Assessment of TN (PGA-TN), where scores range from 1 to 5 and higher score indicates higher severity of symptoms and inability to carry out normal activities
大体时间:3 and 12 months
|
Efficacy of RP-008 with varenicline
|
3 and 12 months
|
|
Change from baseline in Modified Barrow Neurological Institute Pain Intensity Score (BNI), where scores range from I to V and higher score indicates higher pain and need for medication
大体时间:3 and 12 months
|
Efficacy of RP-008 with varenicline
|
3 and 12 months
|
|
Improvement in Patient Global Impression of Change (PGIC) and Clinician Global Impression of Change (CGIC) scale, where scores range from 1 to 7 and higher score indicates worsening of status
大体时间:3 and 12 months
|
Efficacy of RP-008 with varenicline
|
3 and 12 months
|
|
AAV5 anti-capsid and anti-transgene antibody titer
大体时间:12 months
|
Immune response to RP-008
|
12 months
|
|
Vector shedding profile of RP-008
大体时间:12 months
|
Vector shedding in plasma, urine, tears, saliva, and mucus
|
12 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年8月1日
初级完成 (估计的)
2029年2月1日
研究完成 (估计的)
2029年2月1日
研究注册日期
首次提交
2026年4月17日
首先提交符合 QC 标准的
2026年5月12日
首次发布 (实际的)
2026年5月19日
研究记录更新
最后更新发布 (实际的)
2026年6月8日
上次提交的符合 QC 标准的更新
2026年6月4日
最后验证
2026年6月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.